UnknownPhase 3

Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant

China280 participantsStarted 2020-02-01

Plain-language summary

Left ventricular thrombus is a common complication subsequent to ST-segment elevation myocardial infarction (STEMI) that related to increased embolic events. This study aims to assess the efficacy and safety outcomes of Rivaroxaban on the treatment of post-STEMI left ventricular thrombus.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Active bleeding;
✕. History of intracranial hemorrhage;
✕. Clinically significant gastrointestinal bleeding within 12 months before randomization;
✕. Severe thrombocytopenia (\<50x109/L), or Anemia (i.e. Hemoglobin \<90g/L) at screening or pre-randomization;
✕. Liver function Child-Pugh B or C
✕. Untreated arterial aneurysm, arterial or venous malformation and aorta dissection;
✕. Body weight \<40kg
✕. Cardiac shock

What they're measuring

Rate of LVT resolution after triple antithrombotic therapy for 3 month

Timeframe: 3 months

Major bleeding events (ISTH criteria) through the study, an average of 12 weeks

Timeframe: Through the study, an average of 12 weeks

Trial details

NCT IDNCT03764241

SponsorRenJi Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-03-30

Contact for this trial

Jun Pu, Professor

08602168383164 pujun310@hotmail.com

View on ClinicalTrials.gov More ST Segment Elevation Myocardial Infarction trials